CLK1-IN-2

Cat. No.: HY-152219

Molecular Formula: $C_{16}H_{12}Cl_2N_2O_2S$

Molecular Weight: 367.25

Target: CDK

Pathway: Cell Cycle/DNA Damage

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CLK1-IN-2 is metabolically stable Clk1 inhibitor. CLK1-IN-2 has selectivity for Clk1 with an IC_{50} value of 1.7 nM. CLK1-IN-2 can be used for the research of tumour, Duchenne's muscular dystrophy and viral infections such as HIV-1 and influenza[1].
IC_{50} & Target	IC50: 1.7 nM (Clk1)[1].
In Vitro	CLK1-IN-2 (Compound 27a) has selectivity for Clk1 with an IC_{50} value of 1.7 nM[1]. CLK1-IN-2 shows long metabolic half-lives of 6.4 h[1]. CLK1-IN-2exhibits a GI50 of 3.4 μM in T24 cancer cells[1]. CLK1-IN-2 shows a cellular K_i valiue of 0.051 μM in NanoBRET cellular Clk1 engagement assay[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay[1]

Cell Line:	Human dermal fibroblasts
Concentration:	15 μM
Incubation Time:	2 days
Result:	Not affected the proliferation of normal human cells such as fibroblasts.

REFERENCES

[1]. Dalia S El-Gamil, et al. Discovery of novel 5-methoxybenzothiophene hydrazides as metabolically stable Clk1 inhibitors with high potency and unprecedented Clk1 isoenzyme selectivity. Eur J Med Chem. 2022 Dec 15;247:115019.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA